Jingrui Pharmaceutical

Jingrui Pharmaceutical is a private Chinese biotech company focused on discovery and development of innovative small-molecule therapies for oncology and other serious diseases. Founded in 2020 and headquartered in Suzhou, the company appears to concentrate on difficult-to-drug targets and has highlighted targeted protein degradation and other precision small-molecule programs. Publicly available third-party pipeline references indicate programs against KRAS G12D, CDK7, and IRE1, with at least one asset reported at IND stage and several others in preclinical development. The company also appears to maintain operations beyond Suzhou, with references to branches in Shandong and Boston. Overall, Jingrui Pharmaceutical looks like an early-stage oncology-focused biotech building a targeted small-molecule pipeline around high-value cancer biology targets.